Salvatore Cannavo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1811040/publications.pdf

Version: 2024-02-01

164 papers 4,722 citations

94269 37 h-index 61 g-index

194 all docs

194 docs citations

194 times ranked 3761 citing authors

#	Article	IF	CITATIONS
1	Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies. Journal of Endocrinological Investigation, 2022, 45, 1235-1246.	1.8	8
2	Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas. Frontiers in Endocrinology, 2022, 13, 841118.	1.5	5
3	Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY. Journal of Endocrinological Investigation, 2022, 45, 1535-1545.	1.8	2
4	Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life. Endocrine, 2022, 77, 510-518.	1.1	10
5	The prevalence of silent acromegaly in prolactinomas is very low. Journal of Endocrinological Investigation, 2021, 44, 531-539.	1.8	1
6	Influence of Dietary Habits on Oxidative Stress Markers in Hashimoto's Thyroiditis. Thyroid, 2021, 31, 96-105.	2.4	43
7	Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors. Journal of Neuropathology and Experimental Neurology, 2021, 80, 45-51.	0.9	1
8	What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study. Journal of Endocrinological Investigation, 2021, 44, 865-872.	1.8	3
9	What we have to know about corticosteroids use during Sars-Cov-2 infection. Journal of Endocrinological Investigation, 2021, 44, 693-701.	1.8	30
10	Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence. Pituitary, 2021, 24, 483-491.	1.6	5
11	Oxidative stress as a key feature of autoimmune thyroiditis: an update. Minerva Endocrinologica, 2021, 45, 326-344.	1.7	19
12	ESE audit on management of adult growth hormone deficiency in clinical practice. European Journal of Endocrinology, 2021, 184, 323-334.	1.9	14
13	Commentary: L-T4 Therapy in Enteric Malabsorptive Disorders. Frontiers in Endocrinology, 2021, 12, 696768.	1.5	0
14	Factitious Cushing's syndrome, hypopituitarism, and self-provoked skin lesions: when the skin mirrors the soul. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.2	1
15	Global epidemiology of acromegaly: a systematic review and meta-analysis. European Journal of Endocrinology, 2021, 185, 251-263.	1.9	33
16	Recent insights into the pathogenesis of autoimmune hypophysitis. Expert Review of Clinical Immunology, 2021, 17, 1175-1185.	1.3	7
17	Serum Levels of Soluble Receptor for Advanced Glycation End Products Are Reduced in Euthyroid Children with Newly Diagnosed Hashimoto's Thyroiditis: A Pilot Study. Hormone Research in Paediatrics, 2021, 94, 144-150.	0.8	3
18	A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score. Frontiers in Endocrinology, 2021, 12, 747549.	1.5	13

#	Article	IF	CITATIONS
19	Clinical Consequences of Variable Results in the Measurement of Free Thyroid Hormones: Unusual Presentation of a Family with a Novel Variant in the <i>THRB</i> Gene Causing Resistance to Thyroid Hormone Syndrome. European Thyroid Journal, 2021, 10, 533-541.	1.2	2
20	Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report. Journal of Medical Case Reports, 2021, 15, 555.	0.4	2
21	Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly Patients. Experimental and Clinical Endocrinology and Diabetes, 2021, , .	0.6	O
22	High bone marrow fat in patients with Cushing's syndrome and vertebral fractures. Endocrine, 2020, 67, 172-179.	1.1	20
23	Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. Journal of Endocrinological Investigation, 2020, 43, 219-229.	1.8	44
24	Selenium exerts protective effects against oxidative stress and cell damage in human thyrocytes and fibroblasts. Endocrine, 2020, 68, 151-162.	1.1	26
25	Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors. Frontiers in Endocrinology, 2020, 11, 591039.	1.5	4
26	Serum levels of advanced glycation end products (AGEs) are increased and their soluble receptor (sRAGE) reduced in Hashimoto's thyroiditis. Journal of Endocrinological Investigation, 2020, 43, 1337-1342.	1.8	17
27	Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide. Frontiers in Endocrinology, 2020, 11, 28.	1.5	3
28	MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior. Journal of Endocrinological Investigation, 2020, 43, 947-958.	1.8	15
29	Cystic Fibrosis as a Cause of Malabsorption and Increased Requirement of Levothyroxine. Thyroid, 2020, 30, 1095-1096.	2.4	4
30	COVID-19 outbreak and steroids administration: are patients treated for Sars-Cov-2 at risk of adrenal insufficiency?. Journal of Endocrinological Investigation, 2020, 43, 1035-1036.	1.8	22
31	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. Journal of Clinical Medicine, 2019, 8, 1850.	1.0	31
32	Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 856-862.	1.8	23
33	Comment to â€~Glucocorticoid resistance syndrome caused by a novel <i>NR3C1</i> point mutation' by Al Argan <i>et al.</i> . Endocrine Journal, 2019, 66, 657.	0.7	5
34	Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. Pituitary, 2019, 22, 552-560.	1.6	19
35	First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy. Growth Hormone and IGF Research, 2019, 45, 17-19.	0.5	2
36	Cyberknife stereotactic treatment of pituitary adenomas: A single center experience using different irradiation schemes and modalities. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2019, 16, 31-41.	0.2	1

3

#	Article	IF	CITATIONS
37	Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what) Tj ETQq1 1 0.7843	l4 rgBT 1.8	/Overlock 10
38	GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly. Journal of Endocrinological Investigation, 2019, 42, 825-831.	1.8	16
39	Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience. Endocrine Connections, 2019, 8, 528-535.	0.8	47
40	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. Endocrine, 2018, 61, 118-124.	1.1	16
41	The boxer world heavyweight champion Primo Carnera portrayed by Giacomo Balla. Journal of Endocrinological Investigation, 2018, 41, 495-496.	1.8	2
42	Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS). Journal of Endocrinological Investigation, 2018, 41, 1259-1266.	1.8	9
43	Establishment of a protocol to extend the lifespan of human hormone-secreting pituitary adenoma cells. Endocrine, 2018, 59, 102-108.	1.1	4
44	Oral mucositis induced by treatment with soft gel formulation of levothyroxine. Endocrine, 2018, 59, 226-227.	1.1	5
45	How to improve effectiveness of pegvisomant treatment in acromegalic patients. Journal of Endocrinological Investigation, 2018, 41, 575-581.	1.8	18
46	Pituitary atypical teratoid rhabdoid tumor in a patient with prolactinoma: <scp>A</scp> unique description. Neuropathology, 2018, 38, 260-267.	0.7	18
47	Immunohistochemical expression of glypican-3 in adrenocortical carcinoma: A potential cause of diagnostic pitfalls. Annals of Diagnostic Pathology, 2018, 35, 92-93.	0.6	3
48	Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment. Frontiers in Endocrinology, 2018, 9, 358.	1.5	68
49	Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014. Frontiers in Endocrinology, 2018, 9, 95.	1.5	17
50	Vitamin D receptor gene polymorphisms/haplotypes and serum 25(OH)D3 levels in Hashimoto's thyroiditis. Endocrine, 2017, 55, 599-606.	1.1	40
51	A 53â€yearâ€old woman with Cushing's disease and a pituitary tumor. Neuropathology, 2017, 37, 86-90.	0.7	6
52	Pegvisomant in acromegaly: an update. Journal of Endocrinological Investigation, 2017, 40, 577-589.	1.8	53
53	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2454-2464.	1.8	51
54	Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden. Molecular and Cellular Endocrinology, 2017, 457, 81-88.	1.6	17

#	Article	IF	CITATIONS
55	Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma. Endocrine, 2017, 58, 295-302.	1.1	14
56	Acromegaly is associated with increased cancer risk: a survey in Italy. Endocrine-Related Cancer, 2017, 24, 495-504.	1.6	61
57	Effects of mitotane on the hypothalamic–pituitary–adrenal axis in patients with adrenocortical carcinoma. European Journal of Endocrinology, 2017, 177, 361-367.	1.9	25
58	Spontaneous intermittent MRI changes of a pituitary stalk lesion causing diabetes insipidus and amenorrhea. Endocrine, 2017, 56, 217-219.	1.1	1
59	Aggressive Pituitary Adenomas: The Dark Side of the Moon. World Neurosurgery, 2017, 97, 140-155.	0.7	34
60	Commentary on "Co-Occurrence of Pituitary Adenoma With Suprasellar and Olfactory Groove Meningiomas― Basic and Clinical Neuroscience, 2017, 8, 513-515.	0.3	0
61	Multidisciplinary Management of Pituitary Apoplexy. International Journal of Endocrinology, 2016, 2016, 1-11.	0.6	39
62	<scp>ACROSCORE</scp> : a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease. Clinical Endocrinology, 2016, 84, 380-385.	1.2	24
63	Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. Clinical Endocrinology, 2016, 84, 614-619.	1.2	26
64	Acromegaly Is More Severe in Patients With <i>AHR</i> or <i>AIP</i> Gene Variants Living in Highly Polluted Areas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1872-1879.	1.8	34
65	Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. Endocrine, 2016, 54, 762-767.	1.1	30
66	Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. Journal of Neuro-Oncology, 2016, 126, 519-525.	1.4	105
67	Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide. Endocrine, 2016, 52, 481-487.	1.1	12
68	Analysis of BCLI, N363S and ER22/23EK Polymorphisms of the Glucocorticoid Receptor Gene in Adrenal Incidentalomas. PLoS ONE, 2016, 11, e0162437.	1.1	13
69	Cardiovascular outcomes and conventional risk factors in non-diabetic adult patients with GH deficiency: A long-term retrospective cohort study. European Journal of Internal Medicine, 2015, 26, 813-818.	1.0	4
70	Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (Hypo <scp>CCS</scp>) according to tertiles of growth hormone peak concentration following stimulation testing at study entry. Clinical Endocrinology, 2015, 83, 527-535.	1.2	3
71	Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. Journal of Endocrinological Investigation, 2015, 38, 1099-1109.	1.8	12
72	Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA. Journal of Endocrinological Investigation, 2015, 38, 377-382.	1.8	14

#	Article	IF	CITATIONS
73	Effects of GH replacement therapy on thyroid volume and nodule development in GH deficient adults: a retrospective cohort study. European Journal of Endocrinology, 2015, 172, 543-552.	1.9	16
74	ACROSTUDY: the Italian experience. Endocrine, 2015, 48, 334-341.	1.1	38
75	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3231-3244.	1.8	113
76	Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine, 2014, 47, 206-12.	1.1	16
77	MTHFRÂC677T polymorphism, folate status and colon cancer risk in acromegalic patients. Pituitary, 2014, 17, 257-66.	1.6	6
78	Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. Journal of Endocrinological Investigation, 2014, 37, 1017-1030.	1.8	45
79	Increased serum interleukin-22 levels in patients with PRL-secreting and non-functioning pituitary macroadenomas. Pituitary, 2014, 17, 76-80.	1.6	5
80	Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing's disease. Endocrine, 2014, 47, 550-556.	1.1	3
81	Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly. Clinical Endocrinology, 2014, 81, 249-253.	1.2	21
82	Occult leydig cell tumour and androgen-receptor positive breast cancer in a woman with severe hyperandrogenism. Journal of Ovarian Research, 2013, 6, 43.	1.3	7
83	Should aip gene screening be recommended in family members of FIPA patients with R16H variant?. Pituitary, 2013, 16, 238-244.	1.6	23
84	HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies. Endocrine, 2013, 44, 735-743.	1.1	38
85	Prolactin in obese children: a bridge between inflammation and metabolicâ€endocrine dysfunction. Clinical Endocrinology, 2013, 79, 537-544.	1.2	48
86	Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. Clinical Endocrinology, 2013, 79, 211-216.	1.2	11
87	The unusual association of Graves' disease, chronic spontaneous urticaria, and premature ovarian failure: report of a case and HLA haplotype characterization. Arquivos Brasileiros De Endocrinologia E Metabologia, 2013, 57, 748-752.	1.3	4
88	Chronic idiopathic urticaria and Graves' disease. Journal of Endocrinological Investigation, 2013, 36, 531-6.	1.8	13
89	Systemic hypertension counteracts potential benefits of growth hormone replacement therapy on left ventricular remodeling in adults with growth hormone deficiency. Journal of Endocrinological Investigation, 2013, 36, 243-8.	1.8	2
90	Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E165-E172.	1.8	41

#	Article	IF	CITATIONS
91	How to diagnose and manage Cushing's disease during pregnancy, when hypercortisolism is mild?. Gynecological Endocrinology, 2012, 28, 637-639.	0.7	11
92	Course of pregnancies in women with Cushing's disease treated by gamma-knife. Gynecological Endocrinology, 2012, 28, 827-829.	0.7	2
93	Predictors of morbidity and mortality in acromegaly: an Italian survey. European Journal of Endocrinology, 2012, 167, 189-198.	1.9	189
94	First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary, 2012, 15, 57-60.	1.6	54
95	High prevalence of coronary calcifications and increased risk for coronary heart disease in adults with growth hormone deficiency. Journal of Endocrinological Investigation, 2011, 34, 32-37.	1.8	21
96	Pregnancy after azathioprine therapy for ulcerative colitis in a woman with autoimmune premature ovarian failure and Addison's disease: HLA haplotype characterization. Fertility and Sterility, 2011, 95, 2430.e15-2430.e17.	0.5	10
97	Detection of antipituitary and antihypothalamus antibodies to investigate the role of pituitary or hypothalamic autoimmunity in patients with selective idiopathic hypopituitarism. Clinical Endocrinology, 2011, 75, 361-366.	1.2	56
98	Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL. Pituitary, 2011, 14, 328-334.	1.6	17
99	Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case report. Journal of Medical Case Reports, 2011, 5, 301.	0.4	5
100	Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. European Journal of Endocrinology, 2011, 164, 341-347.	1.9	44
101	Spontaneous recovery from isolated post-traumatic central hypogonadism in a woman. Hormones, 2010, 9, 332-337.	0.9	10
102	Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review. Scientific World Journal, The, 2010, 10, 2132-2138.	0.8	36
103	Lymphocytic Hypophysitis: Differential Diagnosis and Effects of High-Dose Pulse Steroids, Followed by Azathioprine, on the Pituitary Mass and Endocrine Abnormalities — Report of a Case and Literature Review. Scientific World Journal, The, 2010, 10, 126-134.	0.8	24
104	Increased prevalence of acromegaly in a highly polluted area. European Journal of Endocrinology, 2010, 163, 509-513.	1.9	76
105	Predictive Role of the Immunostaining Pattern of Immunofluorescence and the Titers of Antipituitary Antibodies at Presentation for the Occurrence of Autoimmune Hypopituitarism in Patients with Autoimmune Polyendocrine Syndromes over a Five-Year Follow-Up. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3750-3757.	1.8	56
106	Unusual magnetic resonance imaging finding in a male with lymphocytic hypophysitis mimicking a pituitary tumor. Journal of Endocrinological Investigation, 2010, 33, 128-129.	1.8	2
107	Dissociated responsiveness of a growth hormone- and thyrotropin-secreting pituitary adenoma to octreotide-long-acting release therapy: The intriguing case of Mister B Journal of Endocrinological Investigation, 2010, 33, 204-205.	1.8	2
108	Primary empty sella: Why and when to investigate hypothalamic-pituitary function. Journal of Endocrinological Investigation, 2010, 33, 343-346.	1.8	40

7

#	Article	IF	CITATIONS
109	N-terminal pro-brain natriuretic peptide determination as a possible marker of cardiac dysfunction in patients with adrenal disorders. Journal of Endocrinological Investigation, 2010, 33, 509-510.	1.8	1
110	High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. European Journal of Endocrinology, 2009, 161, 331-338.	1.9	109
111	Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. European Journal of Endocrinology, 2009, 161, 533-540.	1.9	64
112	Confirmation of local amino acid sequence homology between human prolactin and the amyloid-related proteins. Pituitary, 2009, 12, 368-370.	1.6	2
113	Subcutaneous lipoatrophy induced by longâ€ŧerm pegvisomant administration. Clinical Endocrinology, 2009, 70, 655-656.	1.2	6
114	Unusual endocrine and somatic phenotypic abnormalities in a 14-year-old boy with classic Klinefelter syndrome (47,XXY). Journal of Endocrinological Investigation, 2009, 32, 865-866.	1.8	0
115	Evaluation of myocardial fibrosis by imaging techniques in acromegaly. Clinical Endocrinology, 2008, 69, 685-686.	1.2	0
116	<i>Aryl hydrocarbon receptor interacting protein</i> (<i>AIP</i>) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clinical Endocrinology, 2008, 69, 621-627.	1.2	80
117	Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations. Journal of Endocrinological Investigation, 2008, 31, 946-949.	1.8	8
118	Soluble adhesion molecules levels in patients with Cushing's syndrome before and after cure. Journal of Endocrinological Investigation, 2008, 31, 389-392.	1.8	16
119	Large Genomic Deletions in <i> AIP < /i > in Pituitary Adenoma Predisposition. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4146-4151.</i>	1.8	74
120	Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics Journal, 2008, 8, 357-363.	0.9	35
121	Atrial parasystole in left ventricular noncompaction: a morphofunctional study by echocardiography and magnetic resonance imaging. Journal of Cardiovascular Medicine, 2008, 9, 285-288.	0.6	2
122	Hypophosphatemia as Unusual Cause of ARDS in Cushing's Syndrome Secondary to Ectopic CRH Production. A Case Report. Scientific World Journal, The, 2008, 8, 138-144.	0.8	7
123	Patients with craniopharyngiomas: therapeutical difficulties with growth hormone. Journal of Endocrinological Investigation, 2008, 31, 56-60.	1.8	3
124	Identification of a novel point mutation in the ligand-binding domain of the human glucocorticoid receptor (hGR) in a patient with glucocorticoid resistance. International Journal on Disability and Human Development, 2007, 6, .	0.2	2
125	Pegvisomant in acromegaly: Why, when, how. Journal of Endocrinological Investigation, 2007, 30, 693-699.	1.8	35
126	MRI finding of simultaneous coexistence of growth hormone-secreting pituitary adenoma with intracranial meningioma and carotid artery aneurysms: report of a case. Pituitary, 2007, 10, 299-305.	1.6	52

#	Article	IF	CITATIONS
127	Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: Preliminary report. Journal of Endocrinological Investigation, 2006, 29, 516-522.	1.8	21
128	Lack of Somatostatin Analogs Effectiveness in Gonadotropin-Secreting Pituitary Adenomas. , 2006, 16, 208-213.		1
129	Echocardiographic assessment of subclinical left ventricular eccentric hypertrophy in adult-onset GHD patients by geometric remodeling: an observational case-control study. BMC Endocrine Disorders, 2006, 6, 1.	0.9	8
130	Acromegaly and Coronary Disease: An Integrated Evaluation of Conventional Coronary Risk Factors and Coronary Calcifications Detected by Computed Tomography. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3766-3772.	1.8	75
131	Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease. Clinical Endocrinology, 2005, 63 , $118-119$.	1.2	15
132	Hypopituitarism and rare dermatological diseases: an intriguing case of xanthoma disseminatum. Clinical Endocrinology, 2005, 63, 119-120.	1.2	0
133	Residual Pituitary Function after Brain Injury-Induced Hypopituitarism: A Prospective 12-Month Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6085-6092.	1.8	319
134	Hypopituitarism induced by traumatic brain injury in the transition phase. Journal of Endocrinological Investigation, 2005, 28, 984-989.	1.8	61
135	Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. European Journal of Endocrinology, 2004, 151, 173-178.	1.9	127
136	Correlation between Endocrinological Parameters and Acne Severity in Adult Women. Acta Dermato-Venereologica, 2004, 84, 201-204.	0.6	58
137	Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clinical Endocrinology, 2004, 61, 320-326.	1.2	330
138	Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-γ ligand, rosiglitazone, in Cushing's disease. Journal of Endocrinological Investigation, 2004, 27, RC12-RC15.	1.8	17
139	Prolactin is an amyloid-related protein. Journal of Endocrinological Investigation, 2004, 27, 209-210.	1.8	7
140	Severe head trauma in patients with unexplained central hypothyroidism. American Journal of Medicine, 2004, 116, 767-771.	0.6	39
141	Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing's disease. Journal of Endocrinological Investigation, 2004, 27, RC8-11.	1.8	4
142	Clinical presentation and outcome of pituitary adenomas in teenagers. Clinical Endocrinology, 2003, 58, 519-527.	1.2	82
143	Successive thyroid storms treated with L-carnitine and low doses of Methimazole. American Journal of Medicine, 2003, 115, 417-418.	0.6	22
144	Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. European Journal of Endocrinology, 2003, 149, 195-200.	1.9	77

#	Article	IF	Citations
145	Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. European Journal of Endocrinology, 2003, 148, 31-38.	1.9	55
146	Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. European Journal of Endocrinology, 2002, 147, 461-465.	1.9	18
147	Abnormalities of GH secretion in a young girl with Floating-Harbor syndrome. Journal of Endocrinological Investigation, 2002, 25, 58-64.	1.8	15
148	Abnormalities of hypothalamic-pituitary-thyroid axis in patients with primary empty sella. Journal of Endocrinological Investigation, 2002, 25, 236-239.	1.8	41
149	Impairment of GH secretion in adults with primary empty sella. Journal of Endocrinological Investigation, 2002, 25, 329-333.	1.8	34
150	Exercise-related female reproductive dysfunction. Journal of Endocrinological Investigation, 2001, 24, 823-832.	1.8	31
151	Effectiveness of Slow-Release Lanreotide in Previously Operated and Untreated Patients with GH-Secreting Pituitary Macroadenoma. Hormone and Metabolic Research, 2001, 33, 618-624.	0.7	17
152	Goiter and Impairment of Thyroid Function in Acromegalic Patients: Basal Evaluation and Follow-Up. Hormone and Metabolic Research, 2000, 32, 190-195.	0.7	31
153	Results of a Two-Year Treatment With Slow Release Lanreotide in Acromegaly. Hormone and Metabolic Research, 2000, 32, 224-229.	0.7	31
154	Discussion. Magnetic Resonance Imaging, 1999, 17, 633-636.	1.0	20
155	Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. Journal of Endocrinological Investigation, 1999, 22, 306-309.	1.8	24
156	Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. Journal of Endocrinological Investigation, 1999, 22, 354-359.	1.8	112
157	Granulomatous sarcoidotic lesion of hypothalamic-pituitary region associated with Rathke's cleft cyst. Journal of Endocrinological Investigation, 1997, 20, 77-81.	1.8	14
158	Early-onset cerebellar ataxia, myoclonus and hypogonadism in a case of mitochondrial complex III deficiency treated with vitamins K3 and C. Journal of Neurology, 1995, 242, 203-209.	1.8	22
159	Coexistence of growth hormone-secreting pituitary adenoma and intracranial meningioma: A case report and review of the literature. Journal of Endocrinological Investigation, 1993, 16, 703-708.	1.8	43
160	Effectiveness of computerâ€assisted perimetry in the followâ€up of patients with pituitary microadenoma responsive to medical treatment. Clinical Endocrinology, 1992, 37, 157-161.	1.2	8
161	EFFECTIVENESS OF COMPUTERâ€ASSISTED PERIMETRY IN THE DIAGNOSIS OF PITUITARY ADENOMAS. Clinical Endocrinology, 1989, 31, 673-678.	1.2	5
162	Abnormal responses to vasoactive intestinal peptide and corticotropin releasing hormone during the spontaneous remission of Cushing's disease. Journal of Endocrinological Investigation, 1988, 11, 425-428.	1.8	0

#	Article	lF	CITATIONS
168	Echocardiographic evaluation in acromegalic patients. Journal of Endocrinological Investigation, 1988, 11, 813-814.	1.8	o
164	Abnormal daily periodicity of serum thyrotropin (TSH) and evidence for defective TSH suppression in a case of non-neoplastic syndrome of inappropriate TSH secretion. Journal of Endocrinological Investigation, 1987, 10, 195-202.	1.8	3